| n | Control Outcomes (Pre) | Intervention Outcomes (Post) | Sig (P) |
---|
Pregnancies | Miscarriages (MR%) | Pregnancies | Miscarriages (MR%) | |
---|
RIF | 56 | 0 | 0 (NA) | 44 | 16 (36.4) | 0.015 |
RPL | 46 | 148 | 137 (92.6) | 33 | 13 (39.4) |
< 0.0001
|
- RM2 |
25
| 55 | 51 (92.7) | 17 | 6 (35.3) |
< 0.0001
|
- RM3+ |
19
|
87
|
82 (94.3)
|
15
|
7 (46.7)
|
< 0.0001
|
Other | 32 | 32 | 23 (71.9) | 26 | 15 (57.7) | 0.50 |
Total | 134 | 180 | 160 (89.0) | 103 | 44 (42.7) |
< 0.0001
|
- Population outcomes in the study population (n = 134) both before (Control outcomes) and after (intervention outcomes) immunomodulation, stratified by patient aetiology. RIF patients presented with repeated implantation failure (no pregnancy following at least 2 transfers of good quality embryos). RPL are patients with recurrent pregnancy loss, the RM2 and RM3+ subgroups refer to either 2 or ≥ 3 consecutive losses, while the remainder are non-consecutive losses. “Other” refers to secondary infertility patients with features of RIF/RPL, not meeting the strict criteria for either group. Significance calculated using McNemar’s test